“Shades of Gray” in pancreatic ductal adenocarcinoma: reappraisals on resectability criteria

Pancreatic ductal adenocarcinoma is one of the leading causes of cancer-related deaths and, currently, surgery is the only curative treatment. Patients with borderline resectable pancreatic cancer (BRPC) can benefit from a multidisciplinary approach and R0 resection, and can achieve the same outcome as resectable patients treated with upfront surgery. However, the definition of BRPC changes according to different classifications with a heterogeneous distribution of patients, and it is thus difficult to compare clinical evidence.

Source: Critical Reviews in Oncology Hematology - November 1, 2018 Category: Cancer & Oncology Authors: P. Lombardi, S. Silvestri, D. Marino, M. Santarelli, D. Campra, P. De Paolis, M. Aglietta, F. Leone, On behalf of Rete Oncologica Piemonte e Valle d ’Aosta Source Type: research